These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
31. Comparative responses of three rat strains (DA/Han, Sprague-Dawley and Wistar) to treatment with environmental estrogens. Diel P; Schmidt S; Vollmer G; Janning P; Upmeier A; Michna H; Bolt HM; Degen GH Arch Toxicol; 2004 Apr; 78(4):183-93. PubMed ID: 14689164 [TBL] [Abstract][Full Text] [Related]
32. Reproductive outcomes in rat female offspring from male rats co-exposed to rosuvastatin and ascorbic acid during pre-puberty. Leite GAA; Figueiredo TM; Pacheco TL; Guerra MT; Anselmo-Franci JA; Kempinas WG J Toxicol Environ Health A; 2018; 81(17):873-892. PubMed ID: 30081759 [TBL] [Abstract][Full Text] [Related]
33. Rosuvastatin, a new HMG-CoA reductase inhibitor, upregulates endothelial nitric oxide synthase and protects from ischemic stroke in mice. Laufs U; Gertz K; Dirnagl U; Böhm M; Nickenig G; Endres M Brain Res; 2002 Jun; 942(1-2):23-30. PubMed ID: 12031849 [TBL] [Abstract][Full Text] [Related]
34. Effects of Rosuvastatin on the expression of the genes involved in cholesterol metabolism in rats: adaptive responses by extrahepatic tissues. Ahmadi Y; Haghjoo AG; Dastmalchi S; Nemati M; Bargahi N Gene; 2018 Jun; 661():45-50. PubMed ID: 29605604 [TBL] [Abstract][Full Text] [Related]
35. Assessment of Anti-Xa activity in patients receiving concomitant apixaban with strong p-glycoprotein inhibitors and statins. Milner E; Ainsworth M; Gleaton M; Bookstaver D J Clin Pharm Ther; 2022 May; 47(5):668-675. PubMed ID: 35032137 [TBL] [Abstract][Full Text] [Related]
36. Rosuvastatin: a new HMG-CoA reductase inhibitor for the treatment of hypercholesterolemia. Cheng-Lai A Heart Dis; 2003; 5(1):72-8. PubMed ID: 12549990 [TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of rosuvastatin in treatment of dyslipidemia. McKenney JM Am J Health Syst Pharm; 2005 May; 62(10):1033-47. PubMed ID: 15901588 [TBL] [Abstract][Full Text] [Related]
39. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOE*3-Leiden transgenic mice: evidence for antiinflammatory effects of rosuvastatin. Kleemann R; Princen HM; Emeis JJ; Jukema JW; Fontijn RD; Horrevoets AJ; Kooistra T; Havekes LM Circulation; 2003 Sep; 108(11):1368-74. PubMed ID: 12939225 [TBL] [Abstract][Full Text] [Related]
40. Pharmacodynamic effects and pharmacokinetics of a new HMG-CoA reductase inhibitor, rosuvastatin, after morning or evening administration in healthy volunteers. Martin PD; Mitchell PD; Schneck DW Br J Clin Pharmacol; 2002 Nov; 54(5):472-7. PubMed ID: 12445025 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]